Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Emma Hall

Institute of Cancer Research

United Kingdom

Has grant

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacotherapy

70%

Radiology

30%

Oncology

70%

Radiation Therapy

40%

Patient-reported Outcome

40%

Adjuvant Therapy

40%

Clinical Application

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Recent Grants

Grant: Close

CRUK/14/038 CORE: A randomised trial of conventional care versus radioablation (stereotactic body radiotherapy)for extracranial metastases

Open Date: 2015-11-01

Close Date: 2020-10-31

Grant: Close

CRUK/14/024: HYPO-RT-PC trial - Randomised Phase III study of HYPO-fractionated Radiotherapy in Localised Prostate cancer

Open Date: 2014-12-01

Close Date: 2020-08-31

Grant: Close

A phase II randomised feasibility study of Chemoresection and surgicAl management in Low rIsk non muscle invasive Bladder cancER (CALIBER)

Open Date: 2014-10-01

Close Date: 2017-09-30

Grant: Close

A phase II randomised feasibility study of Chemoresection and surgicAl management in Low rIsk non muscle invasive Bladder cancER (CALIBER)

Open Date: 2014-10-01

Close Date: 2017-09-30

Grant: Close

A phase II randomised feasibility study of Chemoresection and surgicAl management in Low rIsk non muscle invasive Bladder cancER (CALIBER)

Open Date: 2014-10-01

Close Date: 2017-09-30

Articles17

Influence of Comorbidity on Endovascular Thrombectomy Outcomes for Medium‐Vessel Occlusion Stroke: A Nationwide Prospective Observational Study

Article Link

Year:

2025

ESTRO guidelines for developing questionnaires in survey-based radiation oncology research

Article Link

Year:

2025

Impact of on-trial IGRT quality assurance in an international adaptive radiotherapy trial for participants with bladder cancer

Article Link

Year:

2024

Reply to P. de Boissieu et al

Article Link

Year:

2024

“Why am I still suffering?”: Experience of long-term fatigue and neurocognitive changes in oropharyngeal cancer survivors following (chemo)radiotherapy

Article Link

Year:

2024

MRI-guided radiotherapy in twenty fractions for localised prostate cancer; results from the MOMENTUM study

Article Link

Year:

2024

International Society of Urological Pathology (ISUP) Gleason Grade Groups stratify outcomes in the CHHiP Phase 3 prostate radiotherapy trial

Article Link

Year:

2023

A Personalized Clinical Dynamic Prediction Model to Characterize Prognosis for Patients With Localized Prostate Cancer: Analysis of the CHHiP Phase 3 Trial

Article Link

Year:

2023

Clinical trial design for non-muscle-invasive bladder cancer

Article Link

Year:

2023

Machine learning for normal tissue complication probability prediction: Predictive power with versatility and easy implementation

Article Link

Year:

2023

The Association between Acute and Late Genitourinary and Gastrointestinal Toxicities: An Analysis of the PACE B Study

Article Link

Year:

2023

Differences in quality of life and toxicity for male and female patients following chemo (radiotherapy) for bladder cancer

Article Link

Year:

2023

Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non–muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled Trial

Article Link

Year:

2023

A Road Map for Designing Phase I Clinical Trials of Radiotherapy–Novel Agent Combinations

Article Link

Year:

2022

Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial

Article Link

Year:

2021

Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.

Article Link

Year:

2020

Life After COVID-19 for Cancer Clinical Trials.

Article Link

Year:

2020

Collaborators18

Robert Jones

University of Glasgow

UNITED KINGDOM

Louise Murray

Associate Professor and Honorary Consultant Clinical Oncologist

UNITED KINGDOM

Björn Hansen

Danderyd University Hospital

SWEDEN

Douglas Brand

University College London

UNITED KINGDOM

Teresa Ullberg

Lund University

SWEDEN

Pratik Samant

University of Oxford

UNITED KINGDOM

Wei Shen Tan

The University of Texas MD Anderson Cancer Center

UNITED STATES

Stephen Rice

Newcastle University

UNITED KINGDOM

Richard Adams

Professor

Cardiff University

UNITED KINGDOM

Frank Van den Heuvel

University of Oxford

UNITED KINGDOM

Samantha Hinsley

University of Glasgow

UNITED KINGDOM

Ashish Kamat

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

Fay Cafferty

University College London

UNITED KINGDOM

Anna Wilkins

Institute of Cancer Research

UNITED KINGDOM

Ge Yu

Senior Lecturer in Health Economics and Econometrics

King’s College London

UNITED KINGDOM

Chris Hurt

Cardiff University School of Medicine

UNITED KINGDOM

Steven Penegar

Institute of Cancer Research

UNITED KINGDOM

Robert Adam Mitchell

Head of MR-linac Physics

Royal Marsden Hospital Sutton

UNITED KINGDOM

How do I reach out?

Meet Kite AI